JP2023535225A5 - - Google Patents

Info

Publication number
JP2023535225A5
JP2023535225A5 JP2023505388A JP2023505388A JP2023535225A5 JP 2023535225 A5 JP2023535225 A5 JP 2023535225A5 JP 2023505388 A JP2023505388 A JP 2023505388A JP 2023505388 A JP2023505388 A JP 2023505388A JP 2023535225 A5 JP2023535225 A5 JP 2023535225A5
Authority
JP
Japan
Prior art keywords
cancer
lipid nanoparticles
sequence
guanosine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535225A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/043214 external-priority patent/WO2022020811A1/en
Publication of JP2023535225A publication Critical patent/JP2023535225A/ja
Publication of JP2023535225A5 publication Critical patent/JP2023535225A5/ja
Pending legal-status Critical Current

Links

JP2023505388A 2020-07-24 2021-07-26 改変ヌクレオチドを含む脂質ナノ粒子 Pending JP2023535225A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056382P 2020-07-24 2020-07-24
US63/056,382 2020-07-24
PCT/US2021/043214 WO2022020811A1 (en) 2020-07-24 2021-07-26 Lipidnanoparticle comprising modified nucleotides

Publications (2)

Publication Number Publication Date
JP2023535225A JP2023535225A (ja) 2023-08-16
JP2023535225A5 true JP2023535225A5 (cg-RX-API-DMAC7.html) 2024-07-31

Family

ID=77412342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505388A Pending JP2023535225A (ja) 2020-07-24 2021-07-26 改変ヌクレオチドを含む脂質ナノ粒子

Country Status (5)

Country Link
US (1) US20230295257A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185274A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535225A (cg-RX-API-DMAC7.html)
CN (1) CN116710079A (cg-RX-API-DMAC7.html)
WO (1) WO2022020811A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2923757T3 (es) * 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
DK3934673T3 (da) * 2019-03-08 2026-04-07 Massachusetts Inst Technology Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
AU2023262576A1 (en) * 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU744755B2 (en) 1997-11-12 2002-03-07 Brigham And Women's Hospital The translation enhancer element of the human amyloid precursor protein gene
WO2001055371A1 (en) 2000-01-28 2001-08-02 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP5225087B2 (ja) 2005-08-24 2013-07-03 ザ スクリプス リサーチ インスティチュート 翻訳エンハンサーエレメント依存性のベクター系
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2522748A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN101622348A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
EP2225396A4 (en) 2007-11-30 2011-03-02 Univ Ohio State Res Found PROFILING AND SCREENING OF MICRO-RNA EXPRESSION IN PERIPHERAL BLOOD IN LUNG CANCER
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
JP2011517932A (ja) 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病(ccl)と関連するマイクロrnaシグネチャーおよびその使用
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
US20120053224A1 (en) 2008-12-10 2012-03-01 Universitat Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
US20120264626A1 (en) 2009-05-08 2012-10-18 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
KR20120066952A (ko) 2010-12-15 2012-06-25 주식회사 롤팩 7층 구조의 공압출 항균 진공포장 필름 및 그 제조방법
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
JP5965481B2 (ja) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ 皮膚t細胞リンパ腫(ctcl)の診断用マイクロrnaプロファイリング
WO2013033640A1 (en) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
US20140243240A1 (en) 2011-10-26 2014-08-28 Georgetown University microRNA EXPRESSION PROFILING OF THYROID CANCER
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2016187531A1 (en) 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
KR20240144261A (ko) * 2017-02-28 2024-10-02 사노피 치료적 rna
AU2018270111B2 (en) * 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP6715325B2 (ja) siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用
Chen et al. Spleen-targeted mRNA delivery by amphiphilic carbon dots for tumor immunotherapy
ES3054296T3 (en) Method for reducing immunogenicity of rna
AU2016286364B2 (en) ATP-binding cassette family coding polyribonucleotides and formulations thereof
JP7808695B2 (ja) タンパク質発現のためのmRNA及びそのための鋳型
CN116685331A (zh) 用融合相关的小跨膜蛋白配制的蛋白脂质囊泡
JP2024528447A (ja) 非天然型5’非翻訳領域及び3’非翻訳領域、及びその用途
Yihunie et al. Recent advances in messenger ribonucleic acid (mRNA) vaccines and their delivery systems: a review
Rachamala Translational advances in lipid nanoparticle drug delivery systems for cancer therapy: current status and future horizons
JP2018512858A (ja) 癌治療のためのヒト抗原R発現のsiRNA阻害
Copur Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
CN119654141A (zh) 脂质纳米颗粒的组合物
WO2005105136A9 (en) Nanogene therapy for cell proliferation disorders
JP5933674B2 (ja) 癌治療用の組合せ製品
Malhotra et al. SiRNA gene therapy using albumin as a carrier
CN116710079A (zh) 包含经修饰的核苷酸的脂质纳米颗粒
Habibizadeh et al. Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: a review
Lu et al. Novel modifications and delivery modes of cyclic dinucleotides for STING activation in cancer treatment
Huang et al. mRNA vaccines as cancer therapies
JP2025516226A5 (cg-RX-API-DMAC7.html)
WO2025140126A1 (en) Therapeutic ly6k mrna vaccine for cancer
JP2024503000A5 (cg-RX-API-DMAC7.html)
Hang et al. mRNA-based therapies and their clinical prospects
JP2024521803A (ja) ウイルス感染症の予防または治療用ワクチン
CN117384298A (zh) 一种快速规模化生产病毒样颗粒疫苗或药物的方法